---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-052736"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:39:52.425122+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Q3 net income $5.6M ($0.26 EPS); revenue $11.9M; FDA agrees Phase 3 endpoint for APX3330; RYZUMVI approved

## Summary
- Q3 net income $5.6M ($0.26 basic EPS) vs $4.5M loss ($0.22 loss) a year ago; revenue $11.9M from $0.
- Cash $42.4M; management believes sufficient into 2025.
- Successful End-of-Phase 2 FDA meeting for APX3330; Phase 3 endpoint agreed (3-step worsening on DRSS).
- RYZUMVI (phentolamine) FDA approved for mydriasis reversal; Ocuphire received $10M milestone from Viatris.
- VEGA-2 Phase 3 presbyopia trial met primary endpoint; Viatris to continue Phase 3 development in 1H 2024.

## SEC filing metadata
- accession: 0001140361-23-052736
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036123052736/0001140361-23-052736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036123052736/ef20014551_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-052736
- JSON: https://secwatch.observer/filing/0001140361-23-052736.json
- Plain text: https://secwatch.observer/filing/0001140361-23-052736.txt

## Key facts
- Earnings Releases
  Opus Genetics, Inc. reported third quarter ended September 30, 2023 results: revenue $11.9 million.
  - Period: third quarter ended September 30, 2023
  - Revenue: $11.9 million
  - Result: reported results
  source text: License and collaborations revenue was $11.9 million and $17.4 million for the three and nine months ended September 30, 2023, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036123052736/0001140361-23-052736-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.